Professor Marc
Memeber
Pharma
molecular MD corp
Italy
Biography
Marco Manoni joined MolMed as Director of Operations in September 2011 and is Facility Planning & Design Director since March 2013. He has more than 20 years experience in research, development, production and quality management of chemicals and biologicals, diagnostics, nutraceuticals, pharmaceutical intermediates, active pharmaceutical ingredients (API) and investigational medicinal products (IMP). Before joining Molmed, he was a member of the Board of Directors and the Chief Operating Officer at RSM SpA, aR&D Company focused on development and production of intermediates, active pharmaceutical ingredients and investigational medicinal products, as well as Scientific Director of the Chemical-Pharmaceutical group INALCO, for 11 years. Previously, he was inter alia Development and Operation Manager at PRIMM, one of the oldest Italian biotech companies. Marco Manoni holds a Degree in Biology and a Master in Industrial Biotechnology from the State University of Milan. Marco Manoni joined MolMed as Director of Operations in September 2011 and is Facility Planning & Design Director since March 2013. He has more than 20 years experience in research, development, production and quality management of chemicals and biologicals, diagnostics, nutraceuticals, pharmaceutical intermediates, active pharmaceutical ingredients (API) and investigational medicinal products (IMP). Before joining Molmed, he was a member of the Board of Directors and the Chief Operating Officer at RSM SpA, aR&D Company focused on development and production of intermediates, active pharmaceutical ingredients and investigational medicinal products, as well as Scientific Director of the Chemical-Pharmaceutical group INALCO, for 11 years. Previously, he was inter alia Development and Operation Manager at PRIMM, one of the oldest Italian biotech companies. Marco Manoni holds a Degree in Biology and a Master in Industrial Biotechnology from the State University of Milan.
Research Interest
focused on development and production of intermediates, active pharmaceutical ingredients and investigational medicinal products,
